265 related articles for article (PubMed ID: 34153367)
1. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
3. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
4. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
5. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
6. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A; Ramlau R; Falcón González A; Chaudhry A; Todenhöfer T; Tahbaz R; Fontana E; Giannatempo P; Deville JL; Pouessel D; Yoon S; Powles T; Bernat M; Häckl M; Marszewska M; McKernan P; Saulay M; Scaleia F; Engelhardt M; Loriot Y; Siefker-Radtke A; De Santis M
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38627238
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.
Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M
Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828
[TBL] [Abstract][Full Text] [Related]
8. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract][Full Text] [Related]
9. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract][Full Text] [Related]
10. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research.
Necchi A; Raggi D; Volpi CC; Giannatempo P; Colecchia M; Gloghini A
Eur Urol Focus; 2019 Jul; 5(4):689-692. PubMed ID: 28855072
[TBL] [Abstract][Full Text] [Related]
13. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
[TBL] [Abstract][Full Text] [Related]
14. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
Hughes SE
Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
[TBL] [Abstract][Full Text] [Related]
15. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
[TBL] [Abstract][Full Text] [Related]
16. Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
Lötsch D; Kirchhofer D; Englinger B; Jiang L; Okonechnikov K; Senfter D; Laemmerer A; Gabler L; Pirker C; Donson AM; Bannauer P; Korbel P; Jaunecker CN; Hübner JM; Mayr L; Madlener S; Schmook MT; Ricken G; Maaß K; Grusch M; Holzmann K; Grasl-Kraupp B; Spiegl-Kreinecker S; Hsu J; Dorfer C; Rössler K; Azizi AA; Foreman NK; Peyrl A; Haberler C; Czech T; Slavc I; Filbin MG; Pajtler KW; Kool M; Berger W; Gojo J
Acta Neuropathol; 2021 Aug; 142(2):339-360. PubMed ID: 34046693
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Guancial EA; Werner L; Bellmunt J; Bamias A; Choueiri TK; Ross R; Schutz FA; Park RS; O'Brien RJ; Hirsch MS; Barletta JA; Berman DM; Lis R; Loda M; Stack EC; Garraway LA; Riester M; Michor F; Kantoff PW; Rosenberg JE
Cancer Med; 2014 Aug; 3(4):835-44. PubMed ID: 24846059
[TBL] [Abstract][Full Text] [Related]
18. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
19. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
[TBL] [Abstract][Full Text] [Related]
20. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
Cornish EE; Natoli RC; Hendrickson A; Provis JM
Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
